University of Virginia Leads Fibrosis Initiative as Part of a Global Effort to Detect and Treat One of the World’s Most Fatal Conditions
20 juin 2019 15h03 HE
|
University of Virginia School of Engineering
Charlottesville, Va., June 20, 2019 (GLOBE NEWSWIRE) -- Fibrosis is often associated with many of the fatal diseases that pervade our globe, riddling organs with stiff tissue that diminishes their...
Helmsley Charitable Trust Grants $4.3 Million to Develop Tools for the Clinical Testing of Anti-fibrotic Treatments for Crohn’s Disease Patients
15 avr. 2019 12h32 HE
|
The Leona M. and Harry B. Helmsley Charitable Trust
New York, NY, April 15, 2019 (GLOBE NEWSWIRE) -- The Leona M. and Harry B. Helmsley Charitable Trust has awarded $4.3 million to Cleveland Clinic, Mayo Clinic, and Robarts Clinical Trials, Inc. to...
FibroGen Reports Second Quarter 2018 Financial Results
07 août 2018 16h02 HE
|
FibroGen, Inc
Roxadustat U.S. Phase 3 Topline Clinical Data Readout on Track for Fourth Quarter of 2018 Feedback from FDA on Pamrevlumab Pivotal Programs in IPF and in Locally Advanced Unresectable Pancreatic...
ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology
08 janv. 2018 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Jan. 08, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), today announced that it has entered into a research collaboration agreement with Galapagos N.V....
Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Anti-Fibrotic Drug Development Summit 2017
13 nov. 2017 09h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced that Peter G. Traber, M.D.,...
Galectin Therapeutics to Present Clinical Data at The Liver Meeting® 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH Cirrhosis
20 oct. 2017 08h30 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Oct. 20, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that Dr. Raj...
Autoimmune Disease Patent Granted to Galectin Therapeutics
06 juin 2017 08h30 HE
|
Galectin Therapeutics
NORCROSS, Ga., June 06, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has...
Galectin Therapeutics launches the Liver Line, an online community and publication on liver health and liver disease
03 mai 2017 08h30 HE
|
Galectin Therapeutics
NORCROSS, Ga., May 03, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the launch of the Liver...
Galectin Therapeutics to Present at BIO CEO & Investor Conference
08 févr. 2017 08h30 HE
|
Galectin Therapeutics
NORCROSS, Ga., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold...
FibroGen Announces Publication of Pamrevlumab (FG-3019) Clinical Data in Pancreatic Cancer Showing Safety and Improved Survival Outcomes in Combination with Chemotherapy
03 févr. 2017 11h06 HE
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 03, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc., (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that clinical results from the company’s open-label,...